ImmunologyMolecular Therapy — Nucleic AcidsPeer-reviewed
First-in-class Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomas
Pedro Justicia-Lirio, María Tristán‐Manzano, Noelia Maldonado‐Pérez…·Francisco Martín
This paper develops doxycycline-inducible IL-18 CAR-T cells (iTRUCK19.18) that enhance antitumor activity while controlling IL-18 release through dual mechanisms.